A meta-analysis of 13 randomized trials have shown that EGFR TK inhibitors (TKIs) such as gefitinib or erlotinib delay disease progression significantly but do not improve overall survival compared to first line platinum based chemotherapy in Stage IV lung adenocarcinoma harbouring EGFR sensitizing mutations [5]. Here, EGFR is linked to lung adenocarcinoma.